# India Insulin Biosimilars Market > India Insulin Biosimilars Market Research Report: Size, Share, Trend Analysis By Types (Rapid-acting biosimilars, Long-acting biosimilars, Premixed biosimilars) and By Indication (TYPE I DIABETES, TYPE II DIABETES) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.31% - **2024:** $ 0.28 Million - **2025:** $ 0.3 Million - **2035:** $ 0.6 Million - **Key Players:** Sanofi (FR), Boehringer Ingelheim (DE), Mylan (US), Sandoz (CH), Teva (IL), Fresenius Kabi (DE), Celltrion (KR), Amgen (US), Roche (CH) **Report ID:** MRFR/MED/49570-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-insulin-biosimilars-market-51327 --- ## Market Summary ## **India Insulin Biosimilars Market Overview** **As per MRFR analysis, the India Insulin Biosimilars Market Size was estimated at 26.12 (USD Million) in 202****4****.****The India Insulin Biosimilars Market Industry is expected to grow from 45(USD Million) in 202****5****to 300 (USD Million) by 2035. The India Insulin Biosimilars Market CAGR (growth rate) is expected to be around 18.823% during the forecast period (2025 - 2035).** ### **Key India Insulin Biosimilars Market Trends Highlighted** The India insulin biosimilars market is witnessing significant growth driven by several key market drivers. One of the primary factors is the increasing prevalence of diabetes in the country, as India accounts for a considerable portion of the global diabetic population. The Indian government's initiatives to improve healthcare access and affordability have also spurred demand for insulin biosimilars, making treatments more accessible to patients.  Furthermore, rising healthcare costs have prompted both consumers and healthcare providers to seek cost-effective alternatives, positioning biosimilars as a more economical option compared to traditional insulin products.In recent times, the focus on enhancing pharmaceutical manufacturing capabilities in India has opened doors for both domestic and international players.  The government’s push for 'Make in India' underlines the importance of local production, which presents opportunities to explore the development of biosimilars that meet international regulatory standards. The increasing acceptance of biosimilars among healthcare professionals and patients is further bolstered by education and awareness campaigns about their safety and efficacy. Moreover, the rapid advancements in biotechnology and regulatory frameworks that support expedited approvals for biosimilars have led to a vibrant market landscape. The advent of innovative delivery methods, such as pen devices and needle-free systems, is also creating new avenues for growth. With the surge in interest and investment in the biotech sector, alongside favorable government initiatives, there are ample opportunities to capture in the Indian insulin biosimilars market. This dynamic environment suggests that the sector will continue evolving, aligning its offerings with patient needs and healthcare system improvements in India. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **India Insulin Biosimilars Market Drivers** ### Increasing Diabetic Population in India The India Insulin Biosimilars Market Industry is witnessing significant growth due to the increasing number of diabetes cases in the country. According to the Indian Council of Medical Research, India has over 77 million individuals diagnosed with diabetes, and this number is projected to reach 134 million by 2045. As diabetes becomes more prevalent, the demand for insulin and its biosimilars will rise, establishing biosimilars as a crucial segment in diabetes management. The growing awareness and acceptance of biosimilar insulin by healthcare professionals and patients are expected to further propel the market. Leading organizations like the Indian Diabetes Association are actively promoting the efficient management of diabetes, thus aiding the adoption of insulin biosimilars in pharmaceutical practices. ### Cost-Effectiveness of Biosimilars One of the primary drivers for the growth of the India Insulin Biosimilars Market Industry is the cost-effectiveness of biosimilar products compared to their originator biologics. The Government of India has introduced policies aimed at promoting the use of biosimilars to ensure affordable healthcare. With the average cost of insulin biosimilars being approximately 30-40% lower than branded insulins, patients are more inclined to opt for these alternatives. This pricing strategy not only supports patient access but also enhances competition in the pharmaceutical market, thereby fostering innovation. Organizations such as the Association of Pharmaceutical Manufacturers of India have reported a surge in the number of biosimilar approvals, reflecting the industry's shift towards more economically sustainable treatment options. ### Government Initiatives and Policy Support The Indian government's push towards the production and use of biosimilars is a critical driver in the growth of the India Insulin Biosimilars Market Industry. The National Biotechnology Development Strategy aims to enhance the biotechnology sector and increase the accessibility of biologics and biosimilars. With biosimilars expected to capture 30-40% of the market share, the government is facilitating smooth regulatory pathways and incentivizing Research and Development (R&D) to boost domestic production. The Central Drug Standard Control Organization is pursuing the rationalization of the workflows concerning the approval of biosimilars. This is expected to help the firms that are focusing on insulin biosimilar products. These policies are not merely supportive of growth, but also enhance the image of India as a biopharmaceutical manufacturing hub. ### Rising Awareness of Biosimilars There is a growing awareness among healthcare providers and consumers regarding the benefits and safety profiles of biosimilars, which is positively impacting the India Insulin Biosimilars Market Industry. According to a survey conducted by the Ministry of Health and Family Welfare, more than 70% of healthcare professionals now have at least basic knowledge of biosimilars, indicating an increase in acceptance.  Furthermore, public health campaigns emphasizing the reliability and efficacy of biosimilars are helping to reshape perceptions and encourage physicians to prescribe these alternatives.Organizations like the Diabetes Foundation, India, are actively involved in educating patients about the various insulin options available, thus driving the adoption and utilization of insulin biosimilars across the nation. ## **India Insulin Biosimilars Market Segment Insights** ### **Insulin Biosimilars Market Type Insights** The India Insulin Biosimilars Market encompasses a diverse range of types, reflecting the complex needs of diabetes management in the country. Rapid-acting biosimilars are particularly noteworthy as they provide patients with the ability to control postprandial blood sugar levels effectively, thus supporting better glycemic control. This segment captures a significant share, driven by the increasing prevalence of Type 2 diabetes, which is fueled by lifestyle changes, urbanization, and rising obesity rates.  Long-acting biosimilars also hold a prominent position in the market, offering patients convenience by minimizing the frequency of injections while maintaining stable insulin levels throughout the day. The demand for these formulations is rising, especially as healthcare providers emphasize the importance of consistent glycemic control to prevent long-term complications associated with diabetes. Meanwhile, premixed biosimilars combine different types of insulin, catering to patients who may benefit from a more simplified dosing regimen. This segment has been gaining traction due to its user-friendly approach, which appeals to both patients and healthcare practitioners aiming for optimal therapeutic outcomes. The growth of each of these categories is supported by advancements in biotechnology, as well as an increase in public health initiatives recognizing the importance of insulin therapy in diabetes management.  However, the overall acceptance of biosimilars hinges on healthcare professionals' education about their efficacy and safety, as well as the need for regulatory updates and pricing strategies that can enhance affordability. The India Insulin Biosimilars Market continues to evolve, bolstered by these influential segments, which reflect the broader trends of personalization in treatment and the increasing focus on diabetes care management. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Insulin Biosimilars Market Indication Insights** The India Insulin Biosimilars Market focuses significantly on the Indication segment, which consists mainly of Type I Diabetes and Type II Diabetes. Type I Diabetes, characterized by insulin deficiency, often necessitates lifelong insulin therapy, making it a crucial area for biosimilar development. In contrast, Type II Diabetes, linked to insulin resistance and often more prevalent in the adult population, also drives demand for more affordable insulin options.  With the growing prevalence of diabetes in India, influenced by lifestyle changes and dietary habits, the need for effective insulin treatments is rising, thereby boosting the India Insulin Biosimilars Market growth.The government of India has initiated various health programs to support diabetes management, which further enhances the opportunities for market expansion.  Moreover, these biosimilars facilitate cost-effective treatment alternatives, which essential in a nation where healthcare affordability is a priority. Consequently, both Type I and Type II Diabetes represent significant portions of the market, catering to a vast patient population requiring consistent and effective insulin therapies. As healthcare accessibility improves and awareness increases, the demand for biosimilars in these diabetes types is expected to increase, solidifying their importance in India's healthcare landscape. ## **India Insulin Biosimilars Market Key Players and Competitive Insights** The India Insulin Biosimilars Market has evolved significantly over the last decade, driven by the increasing prevalence of diabetes and the rising demand for affordable insulin therapies. As the healthcare landscape in India transforms, several players are emerging, focusing on developing biosimilars that mimic the efficacy and safety of original insulin formulations.  This burgeoning market has attracted both established pharmaceutical giants and new entrants, fostering a competitive environment characterized by innovation and strategic partnerships. Understanding the competitive dynamics, such as market positioning, product differentiation, and pricing strategies, is essential for stakeholders aiming to leverage growth opportunities in this thriving sector.Glenmark Pharmaceuticals has established a strong presence in the Indian Insulin Biosimilars Market, leveraging its robust R&D capabilities and commitment to affordable healthcare.  The company boasts a diverse portfolio of insulin biosimilars, aimed at addressing the growing needs of diabetic patients in India. Its focus on developing high-quality products that meet regulatory requirements assures healthcare providers and patients of safety and efficacy. Glenmark has strategically collaborated with various stakeholders in the healthcare ecosystem, enhancing its distribution channels while fostering awareness around diabetes management. The company's dedication to stringent quality assurance processes and patient-centric approaches further solidifies its competitive edge in the market.Dr. Reddy's Laboratories is another formidable player in the Indian Insulin Biosimilars Market, having developed a suite of insulin biosimilars that cater specifically to the local population's needs. The company holds a commendable reputation for its commitment to innovation and patient access, evidenced by its well-received biosimilar products across various therapeutic categories.  Dr. Reddy's fosters a strong market presence influenced by strategic mergers and acquisitions, which have enhanced its research capabilities and operational efficiencies. The company actively engages in partnerships with healthcare providers, ensuring its products are readily available while reinforcing the importance of diabetes management among patients. Dr. Reddy's unwavering pursuit of quality and affordability positions it strongly in this competitive landscape, enabling it to contribute positively to the overall healthcare landscape in India. ### **Key Companies in the India Insulin Biosimilars Market Include** ## **India Insulin Biosimilars Market Industry Developments** Recent developments in the India Insulin Biosimilars Market reflect significant transformation and growth. The market is witnessing increased participation from several major companies, including Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, and Biocon, which have been advancing their pipelines to enhance access to affordable diabetes treatment. In June 2023, Biocon announced the launch of its insulin biosimilar in India, addressing the growing demand for insulin products in the country, which is home to over 77 million diabetics as per the International Diabetes Federation. In September 2023, Dr. Reddy's Laboratories reported an expansion in its biosimilars portfolio, focusing on additional insulin products to capture market share. Furthermore, in May 2023, Zydus Cadila's expansion into the biosimilars space indicated a commitment toward innovation in diabetes management. Merger and acquisition activities have included Sun Pharmaceutical Industries' potential acquisition discussions with certain mid-size firms to bolster its biosimilars division. The overall market valuation of insulin biosimilars continues to grow significantly due to rising diabetic cases, resulting in increased investments and development efforts across prominent India-based pharmaceutical companies, enhancing competition and product availability. ## **India Insulin Biosimilars Market Segmentation Insights** ### **Insulin Biosimilars Market Type****Outlook** ### **Insulin Biosimilars Market Indication****Outlook** ## Market Drivers ### Advancements in Biotechnology Technological advancements in biotechnology are driving innovation within the insulin biosimilars market. The development of sophisticated manufacturing processes and analytical techniques has enhanced the quality and efficacy of biosimilars. In India, companies are increasingly investing in research and development to create high-quality biosimilars that meet regulatory standards. This focus on innovation not only improves product offerings but also fosters competition within the market, leading to better pricing and availability for patients. As the insulin biosimilars market continues to evolve, these advancements are likely to play a pivotal role in shaping the future landscape of diabetes management in India. ### Rising Healthcare Expenditure The increase in healthcare expenditure in India is a significant driver for the insulin biosimilars market. As the government and private sectors allocate more resources to healthcare, there is a growing emphasis on providing affordable treatment options for chronic diseases like diabetes. The insulin biosimilars market stands to gain from this trend, as increased funding can lead to better healthcare infrastructure and access to medications. Moreover, with healthcare spending projected to rise by approximately 10% annually, the demand for cost-effective biosimilars is likely to grow. This trend indicates a positive outlook for the insulin biosimilars market, as it aligns with the broader goals of improving health outcomes and reducing financial burdens on patients. ### Cost-Effectiveness of Biosimilars Cost considerations are paramount in the Indian healthcare landscape, making the cost-effectiveness of biosimilars a significant driver for the insulin biosimilars market. Biosimilars typically offer a lower price point compared to their reference biologics, which can lead to substantial savings for both patients and healthcare systems. In India, where healthcare affordability is a pressing concern, the introduction of biosimilars can potentially reduce treatment costs by up to 30-40%. This financial incentive encourages healthcare providers to prescribe biosimilars, thereby increasing their market penetration. The insulin biosimilars market is thus likely to witness accelerated growth as more patients gain access to these affordable alternatives, ultimately improving treatment adherence and health outcomes. ### Increasing Prevalence of Diabetes The rising incidence of diabetes in India is a crucial driver for the insulin biosimilars market. With an estimated 77 million people living with diabetes, the demand for effective and affordable insulin therapies is surging. This growing patient population necessitates the availability of biosimilars, which offer a cost-effective alternative to branded insulin products. As healthcare costs continue to escalate, the insulin biosimilars market is likely to expand, providing patients with more accessible treatment options. Furthermore, the increasing prevalence of diabetes-related complications underscores the need for timely and effective management, further propelling the market's growth. The insulin biosimilars market is thus positioned to play a vital role in addressing this public health challenge. ### Regulatory Support for Biosimilars The regulatory environment in India is becoming increasingly supportive of biosimilars, which is a key driver for the insulin biosimilars market. The Indian government has established guidelines that facilitate the approval and commercialization of biosimilars, thereby encouraging pharmaceutical companies to invest in this sector. This regulatory framework aims to ensure the safety and efficacy of biosimilars while promoting competition in the market. As a result, the insulin biosimilars market is expected to benefit from a more streamlined approval process, leading to a greater variety of products available to patients. This supportive regulatory landscape is likely to enhance market growth and accessibility. ## Future Outlook The [Insulin Biosimilars Market](https://www.marketresearchfuture.com/reports/insulin-biosimilars-market-9775) in India is projected to grow at a 7.31% CAGR from 2025 to 2035, driven by increasing diabetes prevalence and cost-effective treatment options. **New opportunities:** - Development of patient-centric digital health platforms - Expansion of biosimilar product lines targeting niche diabetes markets - Strategic partnerships with healthcare providers for integrated care solutions By 2035, the insulin biosimilars market is expected to achieve substantial growth and enhanced accessibility. ## Segment Insights ### By Type: Long-acting biosimilars (Largest) vs. Rapid-acting biosimilars (Fastest-Growing) In the India insulin biosimilars market, long-acting biosimilars currently dominate, capturing a significant share due to their ability to provide stable insulin levels over extended periods. Rapid-acting biosimilars, while smaller in market share, are gaining traction among patients looking for flexible dosing options. The premixed biosimilars, though useful for certain patient profiles, remain a niche choice in the overall market landscape. Growth trends indicate a rising preference for rapid-acting biosimilars, driven by increasing diabetes incidence and the demand for personalized treatment regimens. The long-acting segment benefits from the established efficacy and safety profiles, making it a favored choice for long-term management. However, the fast-paced innovation in rapid-acting formulations is positioning them as a game-changer, appealing to a broader patient base seeking convenience and better lifestyle integration. Long-acting biosimilars (Dominant) vs. Rapid-acting biosimilars (Emerging) Long-acting biosimilars are characterized by their prolonged action, providing patients with a stable insulin release that minimizes the risk of hypoglycemia. This segment has established itself as a reliable option for effective diabetes management, particularly for those requiring consistent insulin delivery. On the other hand, rapid-acting biosimilars are emerging as a vital alternative, appealing to patients for their quick onset of action, allowing for more flexible dosing around meal times. With the increased focus on personalized medicine, both segments are expected to thrive, but long-acting biosimilars will likely continue to hold the dominant position in terms of user preference and market penetration. ### By Indication: Type I Diabetes (Largest) vs. Type II Diabetes (Fastest-Growing) In the India insulin biosimilars market, Type I Diabetes holds the largest share within the indication segment, reflecting a well-established patient base and a consistent demand for insulin therapies. This segment benefits from high awareness and diagnosis rates, leading to significant market penetration and loyalty among healthcare providers and patients alike. On the other hand, Type II Diabetes is rapidly gaining traction as the fastest-growing segment, driven by rising obesity rates, sedentary lifestyles, and increasing prevalence of the condition among the urban population. There is a growing emphasis on managing Type II Diabetes, prompting innovations in insulin delivery and formulations to cater to this expanding demographic. The growth in the Type II Diabetes segment is supported by numerous factors, including the rising awareness of diabetes management, government initiatives promoting healthy lifestyles, and advancements in biosimilar technologies. As patients become more health-conscious and access to healthcare improves, there is a noticeable shift towards early diagnosis and treatment. Pharmaceutical companies are also focusing on developing affordable biosimilars to address the increasing healthcare needs, driving competition in this segment. This dynamic landscape positions Type II Diabetes as an emerging powerhouse in the insulin biosimilars market. Indication: Type I Diabetes (Dominant) vs. Type II Diabetes (Emerging) Type I Diabetes stands out as the dominant indication in the India insulin biosimilars market, characterized by a well-established framework of treatment protocols and an extensive support network for patients. This segment benefits from consistent prescriptions from healthcare professionals and established awareness campaigns that enhance patient education. Conversely, Type II Diabetes is emerging as a significant contender, with a rapidly growing population seeking effective management solutions. The increasing prevalence of Type II Diabetes due to lifestyle factors creates new opportunities for the introduction of innovative insulin biosimilars, catering to a broader audience. Both segments demonstrate unique challenges and advantages, shaping the landscape of diabetes management in the region. ## Competitive Benchmarking The insulin biosimilars market in India is characterized by a dynamic competitive landscape, driven by increasing diabetes prevalence and the need for cost-effective treatment options. Major players such as Sanofi (FR), Boehringer Ingelheim (DE), and Mylan (US) are actively shaping the market through strategic initiatives. Sanofi (FR) focuses on innovation and expanding its biosimilar portfolio, while Boehringer Ingelheim (DE) emphasizes partnerships to enhance its market presence. Mylan (US) is leveraging its extensive distribution network to optimize access to biosimilars, collectively fostering a competitive environment that prioritizes affordability and accessibility. Key business tactics in this market include localizing manufacturing and optimizing supply chains to reduce costs and improve efficiency. The competitive structure appears moderately fragmented, with several players vying for market share. The collective influence of these key players is significant, as they engage in various strategies to capture consumer interest and navigate regulatory landscapes. In October 2025, Sanofi (FR) announced a collaboration with a local Indian biotech firm to enhance its biosimilar production capabilities. This strategic move is likely to bolster Sanofi's operational efficiency and reduce production costs, thereby improving its competitive edge in the Indian market. Such partnerships may also facilitate faster regulatory approvals, allowing for quicker market entry of new products. In September 2025, Mylan (US) launched a new insulin biosimilar aimed at providing a more affordable option for patients. This launch is indicative of Mylan's commitment to addressing the rising demand for cost-effective diabetes treatments. By expanding its product offerings, Mylan is positioning itself as a leader in the biosimilars segment, potentially increasing its market share significantly. In August 2025, Boehringer Ingelheim (DE) entered into a strategic alliance with a technology firm to integrate AI into its drug development processes. This initiative is expected to enhance the efficiency of its R&D efforts, allowing for faster development cycles and improved product quality. The integration of advanced technologies may provide Boehringer Ingelheim with a competitive advantage in the rapidly evolving biosimilars market. As of November 2025, current trends in the insulin biosimilars market include a strong focus on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine how companies position themselves in the market, emphasizing the importance of quality and accessibility in biosimilar offerings. ## Recent News & Developments Recent developments in the India Insulin Biosimilars Market reflect significant transformation and growth. The market is witnessing increased participation from several major companies, including Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, and Biocon, which have been advancing their pipelines to enhance access to affordable diabetes treatment. In June 2023, Biocon announced the launch of its insulin biosimilar in India, addressing the growing demand for insulin products in the country, which is home to over 77 million diabetics as per the International Diabetes Federation. In September 2023, Dr. Reddy's Laboratories reported an expansion in its biosimilars portfolio, focusing on additional insulin products to capture market share. Furthermore, in May 2023, Zydus Cadila's expansion into the biosimilars space indicated a commitment toward innovation in diabetes management. Merger and acquisition activities have included Sun Pharmaceutical Industries' potential acquisition discussions with certain mid-size firms to bolster its biosimilars division. The overall market valuation of insulin biosimilars continues to grow significantly due to rising diabetic cases, resulting in increased investments and development efforts across prominent India-based pharmaceutical companies, enhancing competition and product availability. ## Report Scope | MARKET SIZE 2024 | 0.277(USD Million) | | --- | --- | | MARKET SIZE 2025 | 0.297(USD Million) | | MARKET SIZE 2035 | 0.602(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.31% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Sanofi (FR), Boehringer Ingelheim (DE), Mylan (US), Sandoz (CH), Teva (IL), Fresenius Kabi (DE), Celltrion (KR), Amgen (US), Roche (CH) | | Segments Covered | Type, Indication | | Key Market Opportunities | Emerging regulatory frameworks enhance access and affordability in the insulin biosimilars market. | | Key Market Dynamics | Rising competition and regulatory support drive growth in the insulin biosimilars market, enhancing patient access and affordability. | | Countries Covered | India | ## Frequently Asked Questions **Q: What was the overall market valuation of the India insulin biosimilars market in 2024?** A: The overall market valuation was $0.277 Million in 2024. **Q: What is the projected market valuation for the India insulin biosimilars market in 2035?** A: The projected valuation for 2035 is $0.602 Million. **Q: What is the expected CAGR for the India insulin biosimilars market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 7.31%. **Q: Which companies are considered key players in the India insulin biosimilars market?** A: Key players include Sanofi, Boehringer Ingelheim, Mylan, Sandoz, Teva, Fresenius Kabi, Celltrion, Amgen, and Roche. **Q: What are the segment valuations for rapid-acting biosimilars in 2024?** A: The segment valuation for rapid-acting biosimilars was $0.0835 Million in 2024. **Q: How did the long-acting biosimilars perform in terms of valuation in 2024?** A: The valuation for long-acting biosimilars was $0.1385 Million in 2024. **Q: What is the valuation for premixed biosimilars in 2024?** A: The valuation for premixed biosimilars was $0.055 Million in 2024. **Q: What are the segment valuations for Type I Diabetes in the India insulin biosimilars market?** A: The valuation for Type I Diabetes was $0.111 Million in 2024. **Q: What is the valuation for Type II Diabetes in the India insulin biosimilars market?** A: The valuation for Type II Diabetes was $0.166 Million in 2024. **Q: What is the projected growth trend for the India insulin biosimilars market?** A: The market is expected to grow, reaching $0.602 Million by 2035, indicating a positive trend. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-insulin-biosimilars-market-51327*